MedPath

Effect of Neurofeedback Training on Fatigue Symptoms in Post-COVID Patients with Post-Exertional Mailaise (PEM)

Not Applicable
Recruiting
Conditions
U08.9
U09.9
U10.9
Personal history of COVID-19, unspecified
Post COVID-19 condition, unspecified
Multisystem inflammatory syndrome associated with COVID-19, unspecified
Registration Number
DRKS00032602
Lead Sponsor
niversitätsklinikum Heidelberg, Klinik für Allgemeine Innere Medizin und Psychosomatik (Innere II)
Brief Summary

Not available

Detailed Description

Not available

Recruitment & Eligibility

Status
Recruiting
Sex
All
Target Recruitment
45
Inclusion Criteria

Patients must have a current post-COVID diagnosis with fatigue and PEM symptoms

Exclusion Criteria

Patients who already suffered from previous illnesses that caused fatigue and other ongoing chronic diseases before the COVID infection were excluded from the patient groups. People who suffer from depressive and/or anxious symptoms in addition to fatigue are excluded from the patient groups. This is determined using cut-off scores in the PHQ-9 and GAD-7 (<10 each).
In addition, participants who have already received neurofeedback training must be excluded, since previous experience would influence the result. As a further exclusion criterion, there must be no psychiatric diagnosis (diagnosis groups according to ICD-10: F10-F19 mental and behavioral disorders caused by psychotropic substances; F20-F29 schizophrenia, schizotype and delusional disorders; F30-F39 affective disorders; F40. phobic disorders; F41. Other anxiety disorders; F42.- Obsessive-compulsive disorder). An adjustment disorder (F43) is not an exclusion criterion.
Prior to recruitment, participants will be excluded who are taking the following medications. These are:
• Sympathomimetics (including oral or inhaled beta-2 mimetics)
• Sympatholytics (including beta blockers)
• Parasympathomimetics
• Parasympatholytics
• Sinus node inhibitors (including ivabradine)
• Antiarrhythmics
• Opioids
• Glucocorticoids
• Antidepressants
• Hypnotics/sedatives
• neuroleptics

Study & Design

Study Type
interventional
Study Design
Not specified
Primary Outcome Measures
NameTimeMethod
Secondary Outcome Measures
NameTimeMethod
© Copyright 2025. All Rights Reserved by MedPath